Do we need to innovate new financing mechanism to get access to innovative pharmaceuticals?
In collaboration with Novartis and Bristol-Myers Squibb, BI Norwegian Business School is happy to invite you to this seminar.
Medical research is delivering new therapies that once seemed out of reach. Patients with rare and severe diseases are offered treatment opportunities that can increase quality of life and survival – but these are often costly, and treatment outcomes are uncertain. Financial agreements between hospitals and pharmaceutical companies takes time reach, delaying access for patients.
We expect to see an increasing number of innovative therapies that will be offering valuable treatment prospects to patients, with benefits often accruing over many decades. In this seminar, academic experts and practioners will meet to discuss if new financing mechanisms are needed to better balance governments need of control costs and patients need for early access to promising cures.
Why do we need new payment models, and which models can be adopted?
What are the key (conflicting) goals we are aiming at, and how can new contracts make a difference?
Experience with new payments models and contracts in the UK – and Norway
Adrian Towse from Office of Health Economics (UK) will share his insight, including UK-experiences with new payment models and agreements between the industry and government.
Adrian Towse – Professor Emeritus Office of Health Economics.
Dag Morten Dalen (Moderator) – Professor BI Norwegian Business School